This series on “Progress and Future Direction to Treat Advanced Gastric Cancer” is edited by Prof. Yasuhide Yamada from Comprehensive Cancer Center, National Center for Global Health and Medicine, Japan.
Yasuhide Yamada, MD, PhD, FACP
Director, Comprehensive Cancer Center, National Center for Global Health and Medicine, Professor, Department of Medical Oncology, Hamamatsu University
Professor Yasuhide Yamada is a medical oncologist with expertise in pharmacotherapy of gastrointestinal cancer. He worked to establish scientific evidence through clinical and translational research at National Cancer Center, and Japan Agency for Medical Research and Development for 20 years. His present work focuses on realizing the value of medicine based on real-world big data, and improving quality of diagnosis and treatment by artificial intelligence anywhere in the world.
- Progress of chemotherapy in gastric cancer
- Future perspective of perioperative chemotherapy for gastric cancer
- Indication of neoaduvant chemotherapy for gastric cancer
- European practice and clinical research of chemotherapy for unresectable/metastatic gastric cancer
- Molecular characterization of type 4 gastric cancer
- What is the best candidates of conversion surgery in patients with stage IV gastric cancer?
- Gene therapy for patients with peritoneal dissemination of gastric cancer
- How to use anti-PD-1 antibody in gastric cancer in US
- Liquid biopsy as clinical application in gastric cancer
- Next stage of collaboration in East Asia
The special series “Progress and Future Direction to Treat Advanced Gastric Cancer” was commissioned by the editorial office, Chinese Clinical Oncology without any funding or sponsorship. Yasuhide Yamada is serving as the unpaid Guest Editor for the special series.